| Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines. | |
| | |
MedLine Citation:
|
PMID: 21881917 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Melanoma is one of the most common cancers, and its incidence has continued to increase over the past few decades. Chemotherapy resistance and related defects in apoptotic signaling are critical for the high mortality of melanoma. Effective drugs are lacking because apoptosis regulation in this tumor type is not well understood. The folate pathway has been considered an interesting target for anticancer therapies, and approaches targeting this pathway have recently been extended to melanoma treatment. In this study, the intracellular apoptosis signaling pathways of two melanoma cells lines (SK-MEL-2 and SK-MEL-28) were investigated after treatment with a new experimental antifolate substance (MR36) that targets thymidylate synthase. In both melanoma cell lines, apoptosis induction was triggered by a p53-independent mechanism. MR36-induced apoptosis was associated with a loss of both mitochondrial membrane potential and caspase-3 activation. Induction of cell cycle arrest by MR36 was associated with changes in the expression of key cell cycle regulators, such as p21 and cyclin D1, and the hypophosphorylation of pRb. In addition, Fas signaling was also analyzed. These findings suggest that, unlike classical antifolates, MR36 exerted an inhibitory effect on both the enzymatic function and expression of thymidylate synthase, thereby inducing apoptosis through the activation of the extrinsic and intrinsic pathways in the melanoma cell lines. MR36 showed a different mechanism of action from the known antifolates (Nolatrexed and Pemetrexed) that resulted in higher anticancer activity. Therefore, MR36 should be included as a potential new therapeutic treatment in melanoma research. |
| | |
Authors:
|
Stefania Giudice; Luisa Benassi; Giorgia Bertazzoni; Eugenia Veratti; Daria Morini; Paola Azzoni; Maria P Costi; Alberto Venturelli; Silvia Pirondi; Stefania Seidenari; Cristina Magnoni |
Related Documents
:
|
8111307 - Interleukin 11: an overview. 11884027 - Il-6 a key cytokine in in vitro and in vivo response of sertoli cells to external gamma... 20935477 - Atrosab, a humanized antagonistic anti-tumor necrosis factor receptor one-specific anti... 12214267 - Fr901228, an inhibitor of histone deacetylases, increases the cellular responsiveness t... 14663157 - Mechanical conditioning influences the metabolic response of cell-seeded constructs. 20958987 - Interleukin-33 contributes to both m1 and m2 chemokine marker expression in human macro... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-1 |
Journal Detail:
|
Title: Investigational new drugs Volume: - ISSN: 1573-0646 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-1 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8309330 Medline TA: Invest New Drugs Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Dermatology, University of Modena and Reggio Emilia, Via del Pozzo, 71-41126, Modena, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Anti-neoplastic agent thymoquinone induces degradation of ? and ? tubulin proteins in human cancer c...
Next Document: Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid maligna...